TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16929603

Group type: EXPERIMENTAL
Intervention: Stented ureteroscopic lithotripsy (6 ch DJ stent)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-stented ureteroscopic lithotripsy
Number of subjects: 56
Study: 14643532

Group type: EXPERIMENTAL
Intervention: PREVENAR plus DTP-IPV/Hib
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTP-IPV/Hib alone
Number of subjects: 0
Study: 11153048

Group type: EXPERIMENTAL
Intervention: Cycling exercise at 50% peak oxygen uptake
Number of subjects: 53

Group type: COMPARATOR
Intervention: Seated rest (control session)
Number of subjects: 53
Study: 8616131

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Resection
Number of subjects: 196
Study: 1486524

Group type: EXPERIMENTAL
Intervention: School dental screening intervention (advised by letter for detailed clinical examination)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 528
Study: 2418707

Group type: EXPERIMENTAL
Intervention: 375 Units of Heparin/kg body weight injected into the right atrium (group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 375 Units of Heparin/kg body weight injected into the ascending aorta (group 2)
Number of subjects: 32
Study: 30883159

Group type: EXPERIMENTAL
Intervention: High levels of weight diversity among same-sex peers at school
Number of subjects: 5991
Study: 29371133

Group type: EXPERIMENTAL
Intervention: Inhaled hypertonic saline (HS), 7% NaCl, 4 mL, single dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 minutes after HS
Number of subjects: 0
Study: 27347698

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (10 sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Classic massage (10 sessions)
Number of subjects: 64
Study: 25152289

Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg/kg (Group II)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.075 mg/kg (Group III)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.1 mg/kg (Group IV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline placebo injection (Group I)
Number of subjects: 120
Study: 22580353

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (Consepsis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 40
Study: 20507898

Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 236
Study: 18154225

Group type: EXPERIMENTAL
Intervention: Preventive educational programme including topical application of 1.23% acidulated fluoride phosphate, pH 3.5, every 6 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 58
Study: 15638902

Group type: EXPERIMENTAL
Intervention: Neutral buffered pH (NaH(2)PO(4) buffered to pH 7.5)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Physiological pH (5.0)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 26
Study: 12017398

Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 13
Study: 10361960

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg)
Number of subjects: 126
Study: 7742165

Group type: EXPERIMENTAL
Intervention: Placebo administration to healthy volunteers with behaviour pattern A (competitive and aggressive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration to healthy volunteers with behaviour pattern B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nocebo effect in volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortner score comparison among different groups
Number of subjects: 0
Study: 2373127

Group type: EXPERIMENTAL
Intervention: Cholestyramine 24 g/day for 4 days with piroxicam 20 mg p.o.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cholestyramine 24 g/day for 4 days with tenoxicam 20 mg p.o.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Piroxicam alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tenoxicam alone
Number of subjects: 6
Study: 6930320

Group type: EXPERIMENTAL
Intervention: Regimen A - cytosine arabinoside, 6-thioguanine, plus BCG each month
Number of subjects: 14

Group type: COMPARATOR
Intervention: Regimen B - sequential regimens consisting of azacytidine, cyclophosphamide, prednisone, 6-mercaptopurine, methotrexate, plus BCG
Number of subjects: 14
Study: 31755090

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 886

Group type: COMPARATOR
Intervention: Controlled-release carbamazepine (carbamazepine-CR)
Number of subjects: 886
Study: 29906425

Group type: EXPERIMENTAL
Intervention: Intensive systolic target (≤120 mm Hg)
Number of subjects: 8046

Group type: COMPARATOR
Intervention: Standard systolic target (≤140 mm Hg)
Number of subjects: 8046
Study: 26387583

Group type: EXPERIMENTAL
Intervention: Functional remediation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 188
Study: 24554519

Group type: EXPERIMENTAL
Intervention: Micronutrients (various doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (nonrandomized, no treatment)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Micronutrients (continued treatment)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Micronutrients (stopped treatment)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 64
Study: 22197980

Group type: EXPERIMENTAL
Intervention: 3-day preoperative probiotics (group A, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (group B, n = 30)
Number of subjects: 60
Study: 19643599

Group type: EXPERIMENTAL
Intervention: MMC/5‐FU
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MMC/CDDP
Number of subjects: 40
Study: 17227493

Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation (flutamide 250 mg orally three times/day and leuprolide acetate 7.5 mg injection) for 7 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation for 14 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation for 21 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation for 28 days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pharmacological androgen deprivation (all durations)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Macroarray analysis and QRT-PCR
Number of subjects: 35
Study: 15202756

Group type: EXPERIMENTAL
Intervention: 35 percent hydrogen peroxide gel application for 30 minutes (Group 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 38 percent hydrogen peroxide gel application for 30 minutes (Group 2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide at-home bleaching agent for 60 minutes (combined with Group 1 and Group 2)
Number of subjects: 10
Study: 12002714

Group type: EXPERIMENTAL
Intervention: 99mTc‐DPD
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (oncological out‐patients)
Number of subjects: 8
Study: 10048351

Group type: EXPERIMENTAL
Intervention: 0.5% atropine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 0.25% atropine
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 0.1% atropine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study: 9419625

Group type: EXPERIMENTAL
Intervention: iohexol-300
Number of subjects: 120

Group type: COMPARATOR
Intervention: ioxaglate-320
Number of subjects: 120
Study: 2149055

Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 98
Study: 456997

Group type: EXPERIMENTAL
Intervention: High dosage haloperidol (50 to 100 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Combined therapy (10 mg haloperidol and 150 to 300 mg levomepromazin)
Number of subjects: 33
Study: 31800306

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) up to 2700 mg/day for 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 11
Study: 30466549

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Cocaine craving (Brief Substance Craving Scale)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Anxiety and depression symptoms (Hospital Anxiety and Depression Scale)
Number of subjects: 290
Study: 27272501

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises (PFME) for 6 months, led by individual physiotherapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Written information on PFME (Control group)
Number of subjects: 109
Study: 25460556

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT) - rabeprazole 20 mg and amoxicillin 750 mg, 4 times/day for 14 days (group A1)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Sequential therapy for 10 days (group B1)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Clarithromycin-containing triple therapy for 7 days (group C1)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (HDDT) for 14 days (group A2)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Sequential therapy for 10 days (group B2)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Levofloxacin-containing triple therapy for 7 days (group C2)
Number of subjects: 618
Study: 24060891

Group type: EXPERIMENTAL
Intervention: Central BP intervention (n=144; using SphygmoCor)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care (n=142; using office, home, and 24‐hour ambulatory BP)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 286
Study: 21821078

Group type: EXPERIMENTAL
Intervention: Prebiotic mixture of short chain galacto-oligosaccharides (scGOS)/long chain fructo-oligosaccharides (lcFOS) ratio 9:1 and pectin-derived acidic oligosaccharides (pAOS)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 164
Study: 19164120

Group type: EXPERIMENTAL
Intervention: DIAS-DEDAS eligibility criteria
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 160% mismatch criterion
Number of subjects: 109

Group type: COMPARATOR
Intervention: NPAO patients eligibility after 9 hours vs before 9 hours using DIAS-DEDAS criteria
Number of subjects: 109

Group type: COMPARATOR
Intervention: NPAO patients eligibility after 9 hours vs before 9 hours using 160% criterion
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PAO patients eligibility after 9 hours vs before 9 hours using DIAS-DEDAS criteria
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PAO patients eligibility after 9 hours vs before 9 hours using 160% criterion
Number of subjects: 109
Study: 16552832

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SSP electro-therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 10506613

Group type: COMPARATOR
Intervention: Vinblastine (V) 4 mg/m(2) by intravenous bolus weekly for 6 weeks followed by 2 weeks off
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vinblastine plus estramustine phosphate (EM-V) 600 mg/m(2) PO days 1 through 42, repeated every 8 weeks
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vinblastine plus estramustine phosphate (EM-V)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Vinblastine (V)
Number of subjects: 201
Study: 9484097

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional dental neck fluoridation
Number of subjects: 72
Study: 1864061

Group type: COMPARATOR
Intervention: Coumadin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Revision arthroplasty (combined data)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both IPC and Coumadin
Number of subjects: 149
Study: 6822051

Group type: EXPERIMENTAL
Intervention: Inhalation of radioactive aerosol while sitting, lying, and breathing at an increased rate.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breathing at an increased rate (specifics not provided).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supine position (specifics not provided).
Number of subjects: 0
Study: 31683341

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg BD)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combination of Metformin (500 mg BD) and Pioglitazone (15 mg BD)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combination of Metformin and Pioglitazone
Number of subjects: 106
Study: 29791822

Group type: EXPERIMENTAL
Intervention: Immediate venovenous ECMO
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 249
Study: 26626028

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg)
Number of subjects: 25
Study: 24865525

Group type: EXPERIMENTAL
Intervention: Standard Repeated Mailings (SRM) - 8 booklets mailed over a 12-month period
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Intensive Repeated Mailings (IRM) - 10 booklets and additional supplemental materials mailed monthly over 18 months
Number of subjects: 2349

Group type: COMPARATOR
Intervention: Usual Care (UC) - standard smoking-cessation booklet
Number of subjects: 2349
Study: 23241426

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of 32 metals and elements determined using ICPMS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of Cu, Fe, Mo, Zn
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of As, B, Co, Mn, Se
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of Pb
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of Cr, Fe
Number of subjects: 60
Study: 20170774

Group type: EXPERIMENTAL
Intervention: Manipulative therapy in addition to usual care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 17704021

Group type: EXPERIMENTAL
Intervention: Mixed fruit and vegetable juice concentrates (Juice Plus+R) for 28 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 28 days
Number of subjects: 60
Study: 15790691

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (25‐100 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 13
Study: 12165194

Group type: EXPERIMENTAL
Intervention: Relief Brief acupressure device
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 61
Study: 10207355

Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at the commencement of the study (18-month interval)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at commencement and regular health education throughout the study period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at commencement and subsequent chemotherapy to all children at intervals of 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy to all household members at commencement, subsequent chemotherapy to all children at intervals of 6 months, and regular health education throughout the study period
Number of subjects: 0
Study: 7878975

Group type: EXPERIMENTAL
Intervention: Infusion of 3 × 10^8/kg unaltered donor bone marrow cells perioperatively
Number of subjects: 64

Group type: COMPARATOR
Intervention: Whole organ transplant alone (control group)
Number of subjects: 64
Study: 31756496

Group type: EXPERIMENTAL
Intervention: Brigatinib 90 mg once daily (arm A)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Number of subjects: 222
Study: 31227853

Group type: EXPERIMENTAL
Intervention: 3D planning-assisted with patient-specific custom cutting guides (PSCG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional ancillary system
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3D planning-assisted with PSCG
Number of subjects: 80
Study: 28512009

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50mg administered 1 hour before extinction training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25388434

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion at 2 kcal/min
Number of subjects: 10
Study: 22762896

Group type: EXPERIMENTAL
Intervention: Cognitively Based Compassion Training (CBCT) for 6 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list condition for 6 weeks
Number of subjects: 71
Study: 21522004

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 743

Group type: COMPARATOR
Intervention: Comparator (efavirenz in STARTMRK; optimized background therapy in BENCHMRK)
Number of subjects: 743
Study: 19743899

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 194
Study: 17327945

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40KD) plus ribavirin
Number of subjects: 0
Study: 15459836

Group type: EXPERIMENTAL
Intervention: Walking Programme (WP), n = 11
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (C), n = 10
Number of subjects: 21
Study: 11179521

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 517

Group type: COMPARATOR
Intervention: Aspirin and phenprocoumon
Number of subjects: 517
Study: 10063296

Group type: EXPERIMENTAL
Intervention: Nasal cannula
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ventimask
Number of subjects: 20
Study: 7979564

Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin infusion (one minute of infusion every five minutes)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Continuous oxytocin infusion
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pulsatile oxytocin infusion
Number of subjects: 140
Study: 2567190

Group type: EXPERIMENTAL
Intervention: Active depot neuroleptic injections
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo depot neuroleptic injections
Number of subjects: 54
Study: 60622

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg three times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30175538

Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 127

Group type: COMPARATOR
Intervention: Mindfulness training
Number of subjects: 127
Study: 27301460

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 348

Group type: COMPARATOR
Intervention: Traditional visits
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Telemedicine (rural patients)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Traditional visits (rural patients)
Number of subjects: 348
Study: 25609338

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy tablets containing birch and/or alder or grass pollen allergoids
Number of subjects: 318
Study: 23624785

Group type: EXPERIMENTAL
Intervention: LEUPRO (whey protein and leucine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LEUPRO
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (isocaloric carbohydrate/fat)
Number of subjects: 12
Study: 21454917

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) with gabapentin (up to 1,200 mg/day) for the first 6 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day) alone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 150
Study: 18645136

Group type: EXPERIMENTAL
Intervention: High-dose UV‐A1 phototherapy (130 J/cm²)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medium-dose UV‐A1 phototherapy (65 J/cm²)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Normal skin exposed to UV‐A1 irradiation (70-150 J/cm²)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single high-dose exposure (110-150 J/cm²)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subsequent UV‐A1 exposures after skin darkening
Number of subjects: 18
Study: 16813176

Group type: EXPERIMENTAL
Intervention: Three-part massage therapy (acupoints at the head, abdomen, and back, once daily for 15 days)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Guipi Pills (8 pills each time, thrice daily for 15 days)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Three-part massage therapy
Number of subjects: 166
Study: 12932752

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy for up to 24 months
Number of subjects: 20
Study: 11038198

Group type: EXPERIMENTAL
Intervention: Subtotal thyroid resection (total remnant < 4 ml)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 150
Study: 8777834

Group type: EXPERIMENTAL
Intervention: Intravenous noradrenaline infusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: External compression
Number of subjects: 40
Study: 1394026

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 3903822

Group type: EXPERIMENTAL
Intervention: Estrogen (E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen (A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined estrogen-androgen preparation (E-A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hysterectomized control group with intact ovaries (CON)
Number of subjects: 0
Study: 30324626

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 56

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 56
Study: 27893473

Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 60
Study: 25876736

Group type: EXPERIMENTAL
Intervention: Feedback on progress in mental health symptoms and functioning every 6 months
Number of subjects: 257

Group type: COMPARATOR
Intervention: Feedback on progress in mental health symptoms and functioning as soon as data were entered
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Feedback intervention implementation
Number of subjects: 257